Avecho Biotechnology Limited
AVEFF
$0.0045
-$0.0129-74.14%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 134.13% | 13.11% | -59.44% | -59.93% | -59.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 134.13% | 13.11% | -59.44% | -59.93% | -59.80% |
| Cost of Revenue | -10.79% | 21.85% | 82.24% | 60.66% | 44.92% |
| Gross Profit | 2,172.43% | 0.06% | -126.79% | -113.30% | -103.83% |
| SG&A Expenses | -17.24% | -27.00% | -36.18% | -18.96% | 3.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.36% | -5.83% | -17.47% | -6.62% | 8.46% |
| Operating Income | 11.51% | 9.28% | 8.15% | -10.86% | -42.24% |
| Income Before Tax | 10.26% | 8.61% | 8.04% | -11.03% | -42.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.26% | 8.61% | 8.04% | -11.03% | -42.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.26% | 8.61% | 8.04% | -11.03% | -42.50% |
| EBIT | 11.51% | 9.28% | 8.15% | -10.86% | -42.24% |
| EBITDA | 11.05% | 8.37% | 6.80% | -13.98% | -49.83% |
| EPS Basic | 50.00% | 46.15% | 42.86% | 16.67% | -20.00% |
| Normalized Basic EPS | 33.33% | 42.86% | 50.00% | 28.57% | 0.00% |
| EPS Diluted | 50.00% | 46.15% | 42.86% | 16.67% | -20.00% |
| Normalized Diluted EPS | 33.33% | 42.86% | 50.00% | 28.57% | 0.00% |
| Average Basic Shares Outstanding | 39.73% | 45.85% | 53.21% | 38.50% | 23.41% |
| Average Diluted Shares Outstanding | 39.73% | 45.85% | 53.21% | 38.50% | 23.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |